ReNeuron Group PLC (LSE:RENE) - Overview

Stock Report

ReNeuron Group PLC RENE

Last Price
GBX2.88

Day Change
0.00|0.00%

As of 05/12/2016
07:15:11 GMT | GBX
Minimum 15 Minutes Delay.

Last Close2.88p
Day Range2.80 - 3.68
Mkt Cap91.14Mil
52-Wk Range2.25 - 3.87
Yield %0.00
ISINGB00B0DZML60
Volume16,361,724
P/E-7.19
P/S2,875.00
P/CF-6.48

Share Price

Total Returns 05/12/2016

 Chg (%)  
More ...
ReNeuron Group PLC15.00 
FTSE 100 TR GBP1.22
 
Financials
201420152016
More ...
Income Statement
Turnover0.020.030.03
Operating Profit-7.97-10.39-13.72
Net Profit-7.07-8.91-11.35
Reported EPS-0.50-0.50-0.40
Balance Sheet
Current Assets22.3514.0564.89
Non Current Assets1.772.036.96
Total Assets24.1216.0971.86
Current Liabilities2.042.354.20
Total Liabilities2.402.954.20
Total Equity21.7213.1467.66
Cash Flow
Operating Cash Flow-6.72-9.12-11.92
Net Change in Cash11.37-2.545.04
Broker Forecasts
Year EndingPre-taxEPSEPSgP/EPEGDPSYld %
More ...
'Broker Forecasts' provides consensus figures based on several brokers' views
2017-27.07-0.76--3.79---
2018-32.41-0.91--3.16---

Regulatory News

Director Dealings
TradedActionNotifierPriceAmountValue
More ...
17/02/2016Sale of Option SharesMichael Hunt2.801,763,61649,381.00
17/02/2016Sale of Option SharesMichael Hunt2.81509,55414,313.00
12/02/2016Sale of Option SharesMichael Hunt2.80594,63716,650.00
11/02/2016Sale of Option SharesMichael Hunt2.931,208,33335,413.00

Company Profile

ReNeuron Group PLC and its subsidiaries researches and develops therapies using stem cells. It operates in the business segment of development of cell-based therapies.
 

Sector

Biotechnology

Market Position

901 of 1864 Companies

Index

FTSE AIM All Share

Outlook

(05/12/2016) no outlook statement

Next Event 31/03/2017

Next year end (to be reported)
Ratios
CompSecMkt
More ...
PER (E)-3.3413.5916.10
Div Yld (E)0.004.234.35
PEG (E)0.000.550.19
ROCE-19.44209.79-30.25
Op Mrgn-45,486.21-15.64-33.57
EPS Grwth0.008.6822.86
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00

Broker Sentiment

Strong Buy0
Buy1
Hold0
Sell0
Strong Sell0
  • Strong Sell
  • Strong Buy
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
More ...
Disclaimer
Directors
More ...
ChairmanMr. John Berriman
Chief Executive OfficerMr. Olav Hellebo
Chief Financial Officer & Company SecretMichael Hunt
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at Trafford House, Chester Road, Manchester M32 0RS. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2016 Morningstar. All rights reserved.